Although this cancer relevance inspired the development of CARM1 inhibitors (Kaniskan et al., 2018; Scheer et al., 2019), many small-molecule CARM1 inhibitors lack target selectivity or cellular activity (Kaniskan et al., 2018), two essential criteria of chemical probes (Frye, 2010). The gene discussed is CARM1; the disease is cancer.